Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer A Pietenpol

Showing results (1-10 of 90) with videos related to

Pageof 9
Sort By:
Seminars in Oncology|August 9, 2003
Combined modality management of breast cancer: development of predictive markers through proteomicsBapsi Chakravarthy, Jennifer A Pietenpol
Genes & Development|October 4, 2008
The jury is in: p73 is a tumor suppressor after allJennifer M Rosenbluth, Jennifer A Pietenpol
The Journal of Pathology|October 12, 2013
Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypesBrian D Lehmann, Jennifer A Pietenpol
Cancer Biology & Therapy|May 24, 2005
p53 family members: similar biochemistry, different biologyChristopher E Barbieri, Jennifer A Pietenpol
Carcinogenesis|March 23, 2004
p63: Molecular complexity in development and cancerMatthew D Westfall, Jennifer A Pietenpol
Autophagy|November 13, 2008
mTOR regulates autophagy-associated genes downstream of p73Jennifer M Rosenbluth, Jennifer A Pietenpol
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 12, 2012
Targeting mutant p53 in human tumorsBrian D Lehmann, Jennifer A Pietenpol
Bio-Protocol|March 4, 2021
Tyramide Signal-Amplified Immunofluorescence of MYCN and MYC in Human Tissue Specimens and Cell Line CulturesJohanna M Schafer, Jennifer A Pietenpol
Cell Cycle (Georgetown, Tex.)|February 14, 2007
Transcriptional programs regulated by p63 in normal epithelium and tumorsCarmen A Perez, Jennifer A Pietenpol
Breast (Edinburgh, Scotland)|August 9, 2015
Clinical implications of molecular heterogeneity in triple negative breast cancerBrian D Lehmann, Jennifer A Pietenpol
Pageof 9

Showing results (1-10 of 90) with videos related to

Sort By:
Pageof 9
Seminars in Oncology|August 9, 2003
Combined modality management of breast cancer: development of predictive markers through proteomicsBapsi Chakravarthy, Jennifer A Pietenpol
Genes & Development|October 4, 2008
The jury is in: p73 is a tumor suppressor after allJennifer M Rosenbluth, Jennifer A Pietenpol
The Journal of Pathology|October 12, 2013
Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypesBrian D Lehmann, Jennifer A Pietenpol
Cancer Biology & Therapy|May 24, 2005
p53 family members: similar biochemistry, different biologyChristopher E Barbieri, Jennifer A Pietenpol
Carcinogenesis|March 23, 2004
p63: Molecular complexity in development and cancerMatthew D Westfall, Jennifer A Pietenpol
Autophagy|November 13, 2008
mTOR regulates autophagy-associated genes downstream of p73Jennifer M Rosenbluth, Jennifer A Pietenpol
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 12, 2012
Targeting mutant p53 in human tumorsBrian D Lehmann, Jennifer A Pietenpol
Bio-Protocol|March 4, 2021
Tyramide Signal-Amplified Immunofluorescence of MYCN and MYC in Human Tissue Specimens and Cell Line CulturesJohanna M Schafer, Jennifer A Pietenpol
Cell Cycle (Georgetown, Tex.)|February 14, 2007
Transcriptional programs regulated by p63 in normal epithelium and tumorsCarmen A Perez, Jennifer A Pietenpol
Breast (Edinburgh, Scotland)|August 9, 2015
Clinical implications of molecular heterogeneity in triple negative breast cancerBrian D Lehmann, Jennifer A Pietenpol
Pageof 9